Abbisko Cayman Limited

2256

KYG0028A1085

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 04:08:32 2024-09-20 am EDT			5-day change	1st Jan Change
3.120 ^HKD	+0.97%		+9.09%	-14.52%

Sep. 16	Abbisko Cayman Unit Presents Phase 1 Study for Liver Cancer Drug	MT
Aug. 13	Abbisko Cayman Logs Profit for First Time in H1 on Licensing Gains	MT

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Vous êtes déja client ? Log In

Latest news about Abbisko Cayman Limited

Abbisko Cayman Unit Presents Phase 1 Study for Liver Cancer Drug	Sep. 16	MT
Abbisko Cayman Logs Profit for First Time in H1 on Licensing Gains	Aug. 12	MT
Abbisko Cayman Limited Reports Earnings Results for the Half Year Ended June 30, 2024	Aug. 12	CI
Hong Kong Stocks Rally on Chinese Regulator's Fresh Curbs on Short-Selling	Jul. 11	MT
Abbisko Cayman Expects Swing to Profit in H1; Shares Up 6%	Jul. 11	MT
Abbisko Cayman Limited Provides Unaudited Group Earnings Guidance for the Six Months Ended June 30, 2024	Jul. 10	CI
Hong Kong Stocks Rally on US Rate Cut Hopes, EU's Indecisive on Tariffs on Chinese EVs	Jul. 04	MT
Abbisko Cayman Repurchases to Cancel Over 15 Million Shares for HK$48 Million	Jul. 04	MT
Abbisko Therapeutics Co., Ltd. Presents New Phase II Clinical Data of Its Highly Selective FGFR4 Inhibitor Irpagratinib in Combination with Atezolizumab for the 2024 Esmo-Gi Congress	Jun. 27	CI
Abbisko Cayman Limited commences an Equity Buyback for 70,219,935 shares, representing 10% of its issued share capital, under the authorization approved on June 18, 2024.	Jun. 18	CI
Abbisko Cayman Limited's Equity Buyback announced on March 13, 2024, has expired.	Jun. 17	CI
Abbisko Cayman Unit's Cancer Drug To Be Clinically Tested in Combination with Shanghai Allist's Furmonertinib	May. 08	MT
Abbisko Cayman Limited Appoints Yu Hongping as Joint Company Secretaries	Apr. 29	CI
Abbisko Cayman's Liver Cancer Drug Gets US FDA Orphan Drug Designation	Apr. 25	MT
Abbisko Cayman Limited Voluntary Announcement FGFR4 Inhibitor Irpagratinib Granted Odd by FDA	Apr. 24	CI
Abbisko Cayman Limited Announces Resignation of Tian Huimin as Joint Company Secretary	Apr. 24	CI
Abbisko Cayman's Unit Presents Pre-Clinical Study of Liver Cancer Drug at AACR Annual Meeting	Apr. 09	MT
Abbisko Cayman Completes Patient Enrollment for Phase 3 Trial of Joint Tumor Treatment	Apr. 08	MT
Abbisko Therapeutics Co., Ltd. Completes All Patient Enrollment for the Global Phase III TGCT Trial of Its CSF-1R Inhibitor - Pimicotinib	Apr. 08	CI
Abbisko Cayman's Attributable Loss Narrows as Revenue, Other Gains Rise	Mar. 14	MT
Abbisko Cayman to Buy Back, Cancel Up to HK$100 Million Shares	Mar. 13	MT
Abbisko Cayman Limited commences an Equity Buyback for 70,219,935 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2023.	Mar. 12	CI
Abbisko Cayman Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12	CI
Abbisko Cayman Completes Dosing for Phase 1 Trials for Lung Cancer Treatment	Feb. 22	MT
Abbisko Cayman Receives $70 Million Upfront Payment for Licensing of Tumor Treatment	Feb. 05	MT

Abbisko Cayman Ltd is a China-based clinical-stage biopharmaceutical company. The Company is dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The Company owns two Core Product Candidates, ABSK011 and ABSK091, and 12 other pipeline product candidates. ABSK011 is a potent and highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4). ABSK091 is a molecularly targeted product candidate and a highly potent and selective inhibitor of FGFR subtypes 1, 2 and 3. The Companyâs products are primarily being developed for hepatocellular carcinoma (HCC), urothelial cancer (UC) and gastric cancer (GC).

Employees

258

Sector

Biotechnology & Medical Research

Calendar

2025-03-12 - Q4 2024 Earnings Release (Projected)

More about the company